A Phase 3 Study of HS-20094 in Patients With T2DM
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Type 2 Diabetes
Phase 3
Not yet recruiting
546
2025-09
Industry sponsor intelligence
Jiangsu Hansoh Pharmaceutical Co., Ltd.Clinical Pipeline.
Lead-sponsor view of Jiangsu Hansoh Pharmaceutical Co., Ltd.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 5
- Recruiting
- 0
- Active
- 1
- Completed
- 2
- Results posted
- 0
- Avg enrollment
- 430
Pipeline overview
Programs by phase and activity.
Velocity
Jiangsu Hansoh Pharmaceutical Co., Ltd. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
5phase labels
Early Phase 10
Phase 10
Phase 22
Phase 33
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Dulaglutide → | 2 | 0 | 1 | 1 | 0 | 1 |
| Thymosin Alpha-1 → | 2 | 0 | 1 | 1 | 0 | 0 |
| Linaclotide → | 1 | 0 | 0 | 1 | 0 | 0 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study of HS-20094 in Patients With T2DM
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Type 2 Diabetes
Phase 2
Completed
275
2025-08
Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis B
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Hepatitis B, Chronic
Phase 2
Completed
116
2015-02
Search sponsor records
All Jiangsu Hansoh Pharmaceutical Co., Ltd. studies.
This page groups studies where Jiangsu Hansoh Pharmaceutical Co., Ltd. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
5 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT07156539A Phase 3 Study of HS-20094 in Patients With T2DMSep 5, 2025NCT06901648A Study of HS-20094 in Patients With T2DMAug 1, 2025NCT04804267Evaluation of Clinical Equivalence Between Two Linaclotide Products in the Treatment of Chronic Idiopathic ConstipationMar 18, 2021NCT02366208Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis BFeb 19, 2015NCT02366247Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis BFeb 19, 2015